webinar register page

Chronic Depression: Is Therapeutic Angiogenesis a Breakthrough Treatment?
It’s estimated that 16.2 million adults in the United States, or 6.7 percent of American adults, have had at least one major depressive episode in a given year. Recent research has indicated that the fibroblast growth factor family of proteins, including FGF-1, play important roles in the control of mood and emotions. It has been shown that the levels of FGF-1 drop dramatically in patients that suffer from chronic depression and restoring FGF-1 back to normal levels in the brain represents an attractive therapy to test in patients with major depression.

Sep 22, 2020 02:00 PM in Pacific Time (US and Canada)

Webinar is over, you cannot register now. If you have any questions, please contact Webinar host: dan333@aol.com.